ArticleEye (London, England)2025
Topography-guided, patterned, customized corneal crosslinking for non-invasive astigmatism correction.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo propose and evaluate a novel, non-invasive approach for enduring corneal astigmatism correction based on topography-guided, patterned, customized riboflavin-ultraviolet A corneal collagen crosslinking (CXL).
methodsAstigmatism was modelled on both eyes of rabbits. A randomly selected eye of each rabbit was treated by the proposed CXL procedure with another eye as control. The proposed procedure was performed by a self-built intelligent platform through delivering ultraviolet A lattice in a refined and patterned manner, based on pre-operative corneal topography. The long-term effectiveness, stability, and safety were investigated for 180 days, with topographic measurements, anterior segment optical coherence tomography (AS-OCT), and in vivo corneal confocal microscopy (IVCM).
resultsSpatially selective demarcation lines in AS-OCT images and trabecular patterned hyperdense structure with abundant needle-like processes in IVCM images were detected in the CXL eyes, revealing spatially selective crosslinking. Reductions of astigmatic magnitude (in the steep axis: 0.46 ± 0.28 vs. 2.15 ± 0.58 dioptres, P < 0.001) and high order aberration (0.38 ± 0.18 vs. 0.59 ± 0.19, P = 0.009) with increase of visual strehl ratio (0.21 ± 0.06 vs. 0.13 ± 0.03, P < 0.001) were found in the CXL eyes after CXL and maintained for 180 days, compared to inconspicuous changes in the control eyes. No obvious opacity and inflammation were observed in the CXL eyes, and transient loss of endothelial cells in the treated area was recovered in the subsequent visit.
conclusionsThe proposed novel, non-invasive approach safely fulfilled corneal astigmatism correction with visual quality improvement as well as a decrease in high-order aberration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.